LifeSciences BC > News > Member Announcements

Print Friendly

PhysIQ Closes $8 Million in Series B Financing

July 25, 2017
Quark Venture

PhysIQ Closes $8 Million in Series B Financing • 4490 Ventures and Quark Venture, with partner GF Securities, invest in commercial launch of physIQ VitaLink solution and join Board of Directors • PhysIQ’s go-to-market leverages continuous real-world patient data and personalized analytics to transform both post-acute care and clinical trials implementation • Market traction validates physIQ’s value … Continue reading PhysIQ Closes $8 Million in Series B Financing

New genomics project aims to prevent adverse drug reactions in children

July 25, 2017

Vancouver, BC —The use of medication in modern medicine has revolutionized healthcare and made a significant impact on patient longevity and quality of life. Unfortunately, many medications can also cause unintended side effects – also known as adverse drug reactions (ADRs).  In an effort to reduce severe ADRs in Canada, researchers at the University of … Continue reading New genomics project aims to prevent adverse drug reactions in children

Discovery Parks selects the first three Health Tech companies to participate in the Nimbus Synergies Inc. Investment Program

July 24, 2017
DISCOVERY PARKS

Vancouver, British Columbia, July 24, 2017: Discovery Parks, committed to seeing technology become the most productive, economically important and socially relevant industry in British Columbia, today reported that it has performed an extensive due diligence process and has announced its first three participating companies in the Nimbus Synergies Inc. Investment Program. Approximately $1.5 million dollars … Continue reading Discovery Parks selects the first three Health Tech companies to participate in the Nimbus Synergies Inc. Investment Program

DelMar Pharmaceuticals Receives Approval from China’s Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM

July 24, 2017
DelMar Pharmaceuticals, Inc.

Biomarker-driven clinical trial will explore safety and efficacy of chemoradiation with VAL-083 as an alternative to standard-of-care temozolomide in MGMT-unmethylated GBM VANCOUVER, British Columbia and MENLO PARK, Calif., July 24, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and “the Company”), a biopharmaceutical company focused on the development of new cancer therapies, today announced that … Continue reading DelMar Pharmaceuticals Receives Approval from China’s Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM

Phoenix Molecular Designs Appoints Leading Oncology Expert Dr. Gerrit Los as Chief Scientific Officer

July 18, 2017
PhoenixMD

VANCOUVER, British Columbia and SAN DIEGO, July 17, 2017 /PRNewswire/ — Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics by targeting essential kinases, announced today the appointment of Dr. Gerrit Los as Chief Scientific Officer and a member of the executive management team. Dr. Los brings over 25 years of oncology, … Continue reading Phoenix Molecular Designs Appoints Leading Oncology Expert Dr. Gerrit Los as Chief Scientific Officer

DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

July 18, 2017
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., July 18, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and “the Company”), a biopharmaceutical company focused on the development of new cancer therapies, today announced the completion of the first site initiation visit at the Dent Neurological Institute (“Dent”) for its pivotal Phase 3 Study in Temozolomide-Avastin … Continue reading DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

Qu Biologics invited to present at US National Cancer Institute (NCI) Conference

July 13, 2017
Qu Biologics Inc.

Vancouver, British Columbia – July 12th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, is pleased to announce that CEO Dr. Hal Gunn, was invited to present at the US National Cancer Institute’s Microbial-Based Cancer Therapy Conference … Continue reading Qu Biologics invited to present at US National Cancer Institute (NCI) Conference

DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman

July 12, 2017
DelMar Pharmaceuticals, Inc.

Company Adopts Omnibus Equity Incentive Plan and Policy to Better Align with Shareholder Values and Facilitate Growth VANCOUVER, British Columbia and MENLO PARK, Calif., July 11, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company developing new cancer therapies, today announced that Mr. Saiid Zarrabian has joined the Company’s Board … Continue reading DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman

Sirona Biochem Announces Positive Efficacy Results for Skin Lightening Library

July 6, 2017
Sirona Biochem Corp.

Vancouver, British Columbia – July 6, 2017 – Sirona Biochem Corp. (TSX-V: SBM) (FRANKFURT: ZSB) (Xetra: ZSB) (the “Company”) announced positive preclinical efficacy data for its library of skin lightening compounds. The study was conducted at Bioalternatives in France, a contract research organization specializing in cellular and molecular pharmacology. The study looked at each of … Continue reading Sirona Biochem Announces Positive Efficacy Results for Skin Lightening Library

INSTI HIV Self Test Receives Global Fund Classification for Procurement

July 6, 2017
bioLytical Laboratories

bioLytical’s INSTI approved by UNITAID and Global Fund expert panel RICHMOND, BC, July 6, 2017 /CNW/ – bioLytical Laboratories, a world leader in rapid infectious disease tests, is pleased to announce that its INSTI HIV Self Test has been designated by the Global Fund as eligible for procurement by purchasing entities entitled to access Global … Continue reading INSTI HIV Self Test Receives Global Fund Classification for Procurement